Hepatitis C
📧 Sign up to get email alerts when something new happens for Hepatitis C.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2018-04-19Clinical Trial Update: Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas
A clinical trial evaluating interferon-free antiviral therapy for patients with Hepatitis C-positive genotype 1b–associated indolent non-Hod…
-
CLINICAL_TRIALS withdrawal · 2018-04-17Clinical Trial Update: Improving Fibrosis Outcomes With Metformin [Phase 2]
A Phase 2 trial evaluating metformin for fibrosis outcomes has been withdrawn from the study.
-
CLINICAL_TRIALS withdrawal · 2018-03-22Clinical Trial Update: Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors
A prospective cohort trial evaluating Hepatitis C screening strategies — CDC birth-cohort recommendations versus traditional risk-factor-bas…
-
CLINICAL_TRIALS withdrawal · 2017-11-09Clinical Trial Update: Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4) [Phase 4]
A Phase 4 study evaluating elbasvir/grazoprevir in Brazilian participants with chronic HCV genotype 1 and advanced fibrosis was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-10-25Clinical Trial Update: A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection [Phase 1]
A first-in-human Phase 1 study of AL-611 in healthy volunteers and patients with Hepatitis C has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2017-08-07Clinical Trial Update: Technology-Based Application To Improve The Triple Therapy Adherence Rate In Subjects With Hepatitis C Infection [NA]
A clinical trial evaluating a technology-based application to improve adherence to hepatitis C triple therapy was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-07-12Clinical Trial Update: Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C [Phase 3]
A Phase 3 trial evaluating adding Vitamin D to standard of care for untreated Chronic Hepatitis C in Egyptian patients was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-05-12Clinical Trial Update: Triple Combination DAAs for Treating HCV GT1b Subjects [Phase 2]
A Phase 2 trial evaluating a triple direct-acting antiviral regimen for chronic hepatitis C infection (genotype 1b) has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-05-09Clinical Trial Update: Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism [Phase 4]
A Phase 4 trial evaluating peginterferon alfa-2a and ribavirin with or without telaprevir for genotype 1 Hepatitis C (IL28B CC polymorphism)…
-
CLINICAL_TRIALS withdrawal · 2017-04-28Clinical Trial Update: The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III) [Phase 3]
A Phase 3 trial evaluating adding TCM-700C to standard therapy for hepatitis C genotype 1 was withdrawn from the study. No results were repo…
-
CLINICAL_TRIALS withdrawal · 2017-03-20Clinical Trial Update: A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113) [Phase 4]
Phase 4 trial MK-3034-113 investigating triple therapy for Hepatitis C in insulin-resistant patients who failed dual therapy has been withdr…
-
CLINICAL_TRIALS withdrawal · 2017-01-24Clinical Trial Update: Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance [Phase 3]
A Phase 3 trial evaluating pioglitazone added to pegylated interferon and ribavirin in chronic hepatitis C patients with insulin resistance …
-
CLINICAL_TRIALS withdrawal · 2017-01-09Clinical Trial Update: Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection [NA]
A clinical trial evaluating omega-3 fatty acids (fish oil) in patients with chronic hepatitis C has been withdrawn; no results are reported.
-
CLINICAL_TRIALS withdrawal · 2016-12-05Clinical Trial Update: Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD) [Phase 3]
A Phase 3 trial evaluating Ombitasvir/Paritaprevir/Ritonavir for genotype 1b chronic hepatitis C virus infection in Japanese adults with end…
-
CLINICAL_TRIALS withdrawal · 2016-11-02Clinical Trial Update: A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER) [Phase 3]
A Phase 3 trial (MASTER) evaluating the safety of an individualized combination therapy with ribavirin (Copegus) and peginterferon alfa-2a (…
-
CLINICAL_TRIALS withdrawal · 2016-11-02Clinical Trial Update: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment [Phase 2]
This Phase 2 trial update shows the study of RO5024048 in combination with ritonavir-boosted danoprevir and Pegasys/Copegus in chronic hepat…
-
CLINICAL_TRIALS withdrawal · 2016-10-13Clinical Trial Update: Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1 [Phase 4]
This clinical trial update reports that the Phase 4 study of simeprevir plus sofosbuvir for chronic hepatitis C genotype 1 has been withdraw…
-
EMA withdrawal · 2016-10-06EMA Expired: Incivo (telaprevir) — Janssen-Cilag International N.V.
The EMA page indicates that Incivo (telaprevir) has expired status, associated with chronic hepatitis C, indicating discontinuation or marke…
-
CLINICAL_TRIALS withdrawal · 2016-06-03Clinical Trial Update: Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism [Phase 4]
Phase 4 trial evaluating the impact of hepatitis C treatment on neurocognitive function and brain metabolism has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-02-22Clinical Trial Update: Chronic Hepatitis B and C Recall Northern Holland
A clinical trial in Northern Holland involving Hepatitis B and Hepatitis C is being recalled/withdrawn; status is currently UNKNOWN.
-
CLINICAL_TRIALS withdrawal · 2016-02-02Clinical Trial Update: Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen [Phase 2]
A Phase 2 trial evaluating a triple therapy of asunaprevir, daclatasvir, and BMS-791325 for hepatitis C genotype 4 after failure of pegylate…
-
CLINICAL_TRIALS withdrawal · 2016-01-27Clinical Trial Update: EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C
A multicenter compassionate-use program of daclatasvir plus sofosbuvir, with or without ribavirin, for chronic hepatitis C is no longer avai…
-
CLINICAL_TRIALS withdrawal · 2016-01-20Clinical Trial Update: A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1) [Phase 2]
The Phase 2b trial evaluating the fixed-dose combination of daclatasvir and sofosbuvir for non-cirrhotic, treatment-naive hepatitis C patien…
-
CLINICAL_TRIALS withdrawal · 2016-01-15Clinical Trial Update: A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3 [Phase 2]
Phase 2 randomized, open-label study of daclatasvir and sofosbuvir with or without ribavirin for 8 weeks in treatment-naïve, non-cirrhotic h…
-
CLINICAL_TRIALS withdrawal · 2015-10-22Clinical Trial Update: Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN) [Phase 2]
A Phase 2 trial evaluating regimens of vaniprevir (MK7009) for treatment-naive patients with chronic genotype 1 hepatitis C virus infection …